1. Sonnex K, Alleemudder H, Knaggs R. Impact of smoking status on the efficacy of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review. BMJ Open. 2020;10(4):e037509.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis, and management of COPD. 2022. https://goldcopd.org/gold-reports
3. Sivapalan P, Lapperre TS, Janner J, Laub RR, Moberg M, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet Respir Med. 2019;7(8):699-709.
4. Lee SH, Lee JH, Yoon HI, Park HY, Kim TH, et al. Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts. Respir Res. 2019;20(1):62.
5. Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, et al. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. Adv Ther. 2020;37(6):2956-75.
6. Woods JA, Wheeler JS, Finch CK, et al. Corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 2014;9:421-430.
7. Walters JAE, Tan DJ, White CJ, et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews 2018, Issue 3. Art. No.: CD006897. DOI: 10.1002/14651858.CD006897.pub4.
8. Li L, Zhao N, Ma X, Sun F, He B, et al. Personalized Variable vs Fixed-Dose Systemic Corticosteroid Therapy in Hospitalized Patients With Acute Exacerbations of COPD: A Prospective, Multicenter, Randomized, Open-Label Clinical Trial. Chest. 2021 Nov;160(5):1660-1669.
9. Sivapalan P, Rutishauser J, Ulrik CS, Leuppi JD, Pedersen L,et al. Effect of different corticosteroid regimes for hospitalised patients with exacerbated COPD: pooled analysis of individual participant data from the REDUCE and CORTICO-COP trials. Respir Res. 2021;22(1):155.
10. Rastoder E, Sivapalan P, Eklöf J, Saeed MI, Jordan AS, et al. Systemic Corticosteroids and the Risk of Venous Thromboembolism in Patients with Severe COPD: A Nationwide Study of 30,473 Outpatients. Biomedicines. 2021;9(8):874
11. Miravitlles M, Verhamme K, Calverley PMA, Dreher M, Bayer V, et al. A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid. Int J Chron Obstruct Pulmon Dis. 2022;17:545-58.
12. Hodgens A, Sharman T. Corticosteroids. 2022. In: StatPearls. Treasure Island (FL): StatPearls Publishing; https://www.ncbi.nlm.nih.gov/books/NBK554612/
13. Sivapalan P, Ingebrigtsen TS, Rasmussen DB, Sørensen R, Rasmussen CM, et al. COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months. BMJ Open Respir Res. 2019;6(1):e000407.
14. Patil S, Jadhav A. Short Course of High-dose Steroids for Anaphylaxis Caused Flare Up of Tuberculosis: A Case Report. J Transl Int Med. 2019 Mar 29;7(1):39-42. doi: 10.2478/jtim-2019-0008. PMID: 30997356; PMCID: PMC6463822.
Facebook 
Masuk dengan Email
